3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
7
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid
2
Gastrointestinal Stromal Tumors
2
Bone Marrow Diseases
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Blast Crisis
1
Interventions
Cyclophosphamide
14
fludarabine
10
fludarabine phosphate
8
Whole-Body Irradiation
7
thymoglobulin
5
Thiotepa
5
Tacrolimus
5
Stem Cell Transplantation
5
Nivolumab
5
Granulocyte Colony-Stimulating Factor
5
Busulfan
5
Azacitidine
5
venetoclax
4
Standard of Care
4
Radiotherapy
4
Practice Guidelines as Topic
4
Mycophenolic Acid
4
Methotrexate
4
Melphalan
4
Filgrastim
4
Cytarabine
4
Antilymphocyte Serum
4
Rituximab
3
Mesna
3
Leucovorin
3
Dexamethasone
3
Calcium Dobesilate
3
Alemtuzumab
3
ruxolitinib
2
ceritinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Hematologic Neoplasms
×
nilotinib
×
Clear all
NCT00519090
2011-11-07
ENEST
Novartis
Phase 3
Terminated
6 enrolled
6 charts